Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (3 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Type
(
1 selected
)
Type
Guidance (40)
Guidance programme
(
1 selected
)
Guidance programme
NICE guidelines (1)
Technology appraisal guidance (40)
Apply filters
Showing 31 to 40 of 40
Sort by
Title
Date
Apply sorting
lung cancer
Remove lung cancer filter
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell
lung cancer
(MA review of TA760) [ID6293]
Technology appraisal guidance
13 November 2024
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell
lung cancer
(MA review of TA781) [ID6287]
Technology appraisal guidance
26 February 2025
Sugemalimab with chemotherapy for untreated metastatic non-small-cell
lung cancer
[ID4001]
Technology appraisal guidance
TBC
Tarlatamab for previously treated advanced small-cell
lung cancer
[ID6364]
Technology appraisal guidance
11 December 2024
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell
lung cancer
after 1 or more systemic treatments [ID6253]
Technology appraisal guidance
TBC
Tislelizumab for treating advanced non-small-cell
lung cancer
after platinum-based chemotherapy [ID6161]
Technology appraisal guidance
TBC
Tislelizumab in combination for untreated advanced non-small-cell
lung cancer
[ID6162]
Technology appraisal guidance
TBC
Treatments for non-small-cell
lung cancer
[ID6234]
Technology appraisal guidance
TBC
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell
lung cancer
[ID4061]
Technology appraisal guidance
TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell
lung cancer
[ID1277]
Technology appraisal guidance
TBC
Previous page
1
2
3
Current page
4
Page
4
of
4
Results per page
10
25
50
All
Back to top